A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects

NCT ID: NCT00807846

Last Updated: 2021-02-02

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

201 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-09-30

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This Is A Multicenter, Active-Controlled Trial To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects With Juvenile Idiopathic Arthritis

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arthritis, Juvenile Rheumatoid

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Celecoxib

Group Type EXPERIMENTAL

Celecoxib

Intervention Type DRUG

Celecoxib 50 mg or 100 mg PO BID for 6 weeks

Naproxen

Group Type EXPERIMENTAL

Naproxen

Intervention Type DRUG

Naproxen 7.5 mg/kg PO BID \[maximum of 500 mg BID\] for 6 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Celecoxib

Celecoxib 50 mg or 100 mg PO BID for 6 weeks

Intervention Type DRUG

Naproxen

Naproxen 7.5 mg/kg PO BID \[maximum of 500 mg BID\] for 6 weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Polyarticular (both rheumatoid factor positive and rheumatoid factor negative),oligoarticular and extended oligoarticular JIA for ≥3 months meeting the International League of Associations for Rheumatology (ILAR) criteria for Juvenile Idiopathic Arthritis (JIA)
* Subjects with Systemic JIA with active arthritis in at least 1 joint but without active systemic features are eligible
* ≥2 years of age and \<18 years of age prior to the Baseline visit
* Body weight ≥10 kg at the Baseline visit
* Candidate for chronic NSAID therapy in the Investigator's judgment

Exclusion Criteria

* Psoriatic arthritis, enthesitis-related arthritis, and undifferentiated arthritis types of JIA
* Active systemic features over the prior 12 weeks in children with systemic Juvenile Idiopathic Arthritis (JIA)
* Subjects with psoriatic arthritis, enthesitis-related arthritis, and undifferentiated arthritis should be excluded
* Subjects with active Systemic JIA should not be enrolled
Minimum Eligible Age

2 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Catalina Pointe Clinical Research, Inc.

Tucson, Arizona, United States

Site Status

Arkansas Children's Hospital

Little Rock, Arkansas, United States

Site Status

Children's Hospital-San Diego

San Diego, California, United States

Site Status

Connecticut Children's Medical Center

Hartford, Connecticut, United States

Site Status

Children's National Medical Center / Division of Rheumatology

Washington D.C., District of Columbia, United States

Site Status

Arthritis Associates of South Florida

Delray Beach, Florida, United States

Site Status

Delray Research Associates

Delray Beach, Florida, United States

Site Status

Miami Children's Hospital

Miami, Florida, United States

Site Status

Administrative Site-Hawaii Pacific Health Research Institute

Honolulu, Hawaii, United States

Site Status

Kapiolani Medical Center for Women and Children

Honolulu, Hawaii, United States

Site Status

Kosair Charities Pediatric Clinical Research Unit - University of Louisville

Louisville, Kentucky, United States

Site Status

Kosair Children's Hospital

Louisville, Kentucky, United States

Site Status

University of Louisville

Louisville, Kentucky, United States

Site Status

University Pediatric Rheumatology of Kentucky

Louisville, Kentucky, United States

Site Status

Children's Hospital and Medical Center

Omaha, Nebraska, United States

Site Status

University of Nebraska Medical Center Pediatric Research Office

Omaha, Nebraska, United States

Site Status

Akron Children's Hospital

Akron, Ohio, United States

Site Status

Milton S. Hershey Medical Center

Hershey, Pennsylvania, United States

Site Status

Hospital Regional de Concepcion Guillermo Grant Benavente

Concepción, Región del Biobío, Chile

Site Status

Hospital Roberto del Rio

Santiago, RM, Chile

Site Status

Instituto de Atencion Pediatrica

San José, , Costa Rica

Site Status

Clinica San Borja/Centro de Investigacion de Reumatologia

San Borja, Lima region, Peru

Site Status

Clinica Ricardo Palma/Sitio de Investigacion de Reumatologia

San Isidro, Lima region, Peru

Site Status

Philippine General Hospital

Manila, , Philippines

Site Status

University of Santo Tomas Hospital

Manila, , Philippines

Site Status

State Healthcare Institution of Moscow "Izmailovskaya City Children's Hospital"

Moscow, , Russia

Site Status

First Moscow State Medical University I.M. Sechenov of the Minzdravsocrazvitiya of Russia

Moscow, , Russia

Site Status

Smolensk Regional Clinical Hospital

Smolensk, , Russia

Site Status

SEIHPE "Smolensk State Medical Academy"of the Minzdravsocrazvitiya of Russia

Smolensk, , Russia

Site Status

Institute of Rheumatology

Belgrade, , Serbia

Site Status

Children's Clinic of Internal Medicine

Niš, , Serbia

Site Status

Clinical Research Unit

Pretoria, Gauteng, South Africa

Site Status

CHUV - Unit of Immuno-Allergology and Rhumatology

Ch-1011 Lausanne, , Switzerland

Site Status

Universitaets-Kinderspital

Ch-8032 Zuerich, , Switzerland

Site Status

Department of Cardioreumatology

Kharkiv, , Ukraine

Site Status

Institute of Pediatrics, Obstetrics and Gynecology

Kiev, , Ukraine

Site Status

Kyiv City Children Clinical Hospital #1

Kyiv, , Ukraine

Site Status

Crimean State Medical University, Chair of Pediatrics with a course of Children Infectious Diseases

Simferopol, , Ukraine

Site Status

Zaporizhzhya Regional Clinical Pediatric Hospital

Zaporizhzhya, , Ukraine

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Chile Costa Rica Peru Philippines Russia Serbia South Africa Switzerland Ukraine

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A3191342

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Pharmacokinetics of SP-104
NCT05002946 COMPLETED PHASE1
Effects of Naproxen on Physical Performance
NCT00410995 TERMINATED PHASE4
Actual Use Trial of Naproxen Sodium
NCT01427803 COMPLETED PHASE3
Naproxen Sodium ER Pharmacokinetic Study
NCT00818415 COMPLETED PHASE1